<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747746</url>
  </required_header>
  <id_info>
    <org_study_id>12-139</org_study_id>
    <nct_id>NCT01747746</nct_id>
  </id_info>
  <brief_title>Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study</brief_title>
  <acronym>ARC</acronym>
  <official_title>Anticoagulation With Rivaroxaban in Post Cardioversion Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John H. Stroger Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cook County Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>John H. Stroger Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine that a new drug called &quot;Rivaroxaban®&quot; is effective
      in preventing patients from forming clots after their heart rhythm has been reset by the
      cardiologist with an electrical device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient who are electrically cardioverted require 1 month of anticoagulation (blood thinner).
      Rivaroxaban a Xa-inhibitor has been shown to be non-inferior to Warfarin (Vit K antagonist)
      the current standard of care in many treatment areas. Rivaroxaban will be compared to
      Warfarin historical control group studying the safety and efficacy in electrically
      cardioverted patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombosis</measure>
    <time_frame>30 days</time_frame>
    <description>Number of cerebrovascular accidents, thrombus and embolism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Monitor the 30 day mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>30 days</time_frame>
    <description>Hospitalizations for thrombus or adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>The incidence of major and minor bleeding (as defined under 'safety measures')</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <condition>Thrombo-embolism</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin and Enoxaparin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin and Enoxaparin</intervention_name>
    <description>Historical Control</description>
    <arm_group_label>Warfarin and Enoxaparin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with non-valvular atrial fibrillation requiring electrical cardioversion o
             Atrial fibrillation of unknown duration

        Exclusion Criteria:

          -  Patients requiring extended anticoagulation after cardioversion due to concomitant
             risk factors as defined by CHADS2 score ≥ 1

          -  Significant renal dysfunction (CrCl &lt;15mL/min)

          -  Significant hepatic dysfunction (Childs-Pugh Class B or C)

          -  History of coagulopathy

          -  Active bleeding

          -  Hypersensitivity to Rivaroxaban

          -  Concomitant use of anticoagulants

          -  Concomitant use of potent CYP3A4/P-gp inhibitors or inducers

          -  Interventions requiring interruption of therapy

          -  Pregnancy

          -  Age &lt;18 y/o

          -  History of GI Bleed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pete Antonopoulos, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cook County Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asinul Ansari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cook County Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cook County Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>John H. Stroger Hospital</investigator_affiliation>
    <investigator_full_name>Pete Antonopoulos</investigator_full_name>
    <investigator_title>Clinical Pharmacist- Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Rivaroxaban</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Stroke</keyword>
  <keyword>Thrombo-embolism</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

